Shangya Technology Co., Ltd. (TPEX:6130)
22.80
0.00 (0.00%)
Jun 4, 2026, 9:54 AM CST
Shangya Technology Revenue
Shangya Technology had revenue of 39.34M TWD in the quarter ending March 31, 2026, a decrease of -0.90%. This brings the company's revenue in the last twelve months to 154.38M, down -22.05% year-over-year. In the year 2025, Shangya Technology had annual revenue of 154.74M, down -20.79%.
Revenue (ttm)
154.38M
Revenue Growth
-22.05%
P/S Ratio
6.54
Revenue / Employee
4.98M
Employees
31
Market Cap
1.01B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 154.74M | -40.62M | -20.79% |
| Dec 31, 2024 | 195.35M | -35.76M | -15.47% |
| Dec 31, 2023 | 231.12M | 145.95M | 171.36% |
| Dec 31, 2022 | 85.17M | -18.65M | -17.96% |
| Dec 31, 2021 | 103.82M | -34.06M | -24.70% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Lotus Pharmaceutical | 24.42B |
| PharmaEssentia | 17.50B |
| Ma Kuang Healthcare Holding | 1.08B |
| Concord Medical | 964.35M |
| Anxo Pharmaceutical | 843.26M |
| Wiltrom | 312.43M |
| GeneReach Biotechnology | 232.55M |
| Lukas Biomedical | 179.49M |